Dr. Renger joined Cerevel Therapeutics from Imbrium Therapeutics L.P., where he served as vice president of research and development and regulatory affairs, leading the company’s overall scientific direction and clinical development strategy. Previously, Dr. Renger held roles of increasing responsibility at Merck & Co. over a 15-year tenure, most recently serving as associate vice president.

Dr. Renger was a postdoctoral fellow at the Massachusetts Institute of Technology Center for Learning and Memory and previously worked at the RIKEN Brain Science Institute in Japan. Dr. Renger earned his Ph.D. in biological sciences with a focus on neurogenetics at the University of Iowa where he also completed his B.S. in biology.